Basics Ardelyx, Inc. Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. IPO Date: June 19, 2014 Sector: Healthcare Industry: Biotech Market Cap: $1.57B Activated in VL: True Average Daily Range Avg Daily Range: $0.23 | 3.23% Avg Daily Range (30 D): $0.09 | 1.65% Avg Daily Range (90 D): $0.10 | 2.36% Institutional Daily Volume Avg Daily Volume: 2.38M Avg Daily Volume (30 D): 3.62M Avg Daily Volume (90 D): 4.33M Trade Size Avg Trade Size (Sh.): 266 Avg Trade Size (Sh.) (30 D): 175 Avg Trade Size (Sh.) (90 D): 205 Institutional Trades Total Inst.Trades: 1,449 Avg Inst. Trade: $2.2M Avg Inst. Trade (30 D): $1.69M Avg Inst. Trade (90 D): $1.61M Avg Inst. Trade Volume: .43M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.93M Avg Closing Trade (30 D): $1.94M Avg Closing Trade (90 D): $1.87M Avg Closing Volume: 551.44K     News Jun 2, 2025 @ 5:50 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: N/A May 21, 2025 @ 12:00 PM Ardelyx to Participate at the Jefferies Global Hea... Source: N/A Apr 24, 2025 @ 12:01 PM Ardelyx Announces Three Abstracts Accepted for Pos... Source: N/A Feb 19, 2025 @ 1:01 PM Ardelyx to Present at the TD Cowen 45th Annual Hea... Source: Ardelyx, Inc. Jan 6, 2025 @ 1:00 PM Ardelyx to Present at the 43rd Annual J.P. Morgan ... Source: N/A Financials   TTM Q2 2025 Q1 2025 Basic EPS $-.23 $-.08 $-.17 Diluted EPS $-.23 $-.08 $-.17 Revenue $ 386.15M $ 97.66M $ 74.11M Gross Profit $ 327.45M $ 85.26M $ 61.81M Net Income / Loss $ -56.39M $ -19.08M $ -41.14M Operating Income / Loss $ -40.39M $ -14.4M $ -36.35M Cost of Revenue $ 58.7M $ 12.4M $ 12.3M Net Cash Flow $ 48.16M $ 59.24M $ -34.12M PE Ratio